Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard Dosing.

Clinical pharmacokinetics - 1 Jul 2025

Vos Cornelis F, Coenen Marieke J H, Ter Hark Sophie E, Schellekens Arnt F A, Aarnoutse Rob E, Janzing Joost G E, Ter Heine Rob

Abstract excerpt

BACKGROUND AND OBJECTIVE: Nortriptyline, a tricyclic antidepressant, has an important role in the pharmacotherapy of major depressive disorder (MDD). Individualized dosing approaches, such as pharmacogenetics-based and phenotype-based dosing, may enhance early achievement of therapeutic plasma concentrations, but their comparative accuracy has not been investigated. Our objective was to compare the accuracy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Tricyclic
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Major Depressive Disorder

Share to Models, Biological

Share to Pharmacogenetics

Share to Precision Medicine

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 40413686
DOI: 10.1007/s40262-025-01528-x
PMCID: PMC12185566

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimizing Nortriptyline Dosing: A Comparison between Pharmacogenetics-Based, Phenotype-Based, and Standard Dosing.PMID 40413686Read ↗

Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateSemantic proximity Read ↗

Precision dosing for patients on tricyclic antidepressants.Semantic proximity Read ↗

Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).Semantic proximity Read ↗

Quantitative pharmacogenetics of nortriptyline: a novel approach.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.Semantic proximity Read ↗

Pharmacogenetics-guided dose modifications of antidepressants.Semantic proximity Read ↗

Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studiesSemantic proximity Read ↗

Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial.Semantic proximity Read ↗

Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic toolsSemantic proximity Read ↗

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic ReportSemantic proximity Read ↗

Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.